- Home
- BIAF
as 11-21-2024 4:00pm EST
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN ANTONIO |
| Market Cap: | 21.4M | IPO Year: | 2022 |
| Target Price: | $6.00 | AVG Volume (30 days): | 102.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.20 - $3.62 | Next Earning Date: | 11-14-2024 |
| Revenue: | $9,367,785 | Revenue Growth: | 2813.87% |
| Revenue Growth (this year): | 302.41% | Revenue Growth (next year): | 15.00% |
Latest bioAffinity Technologies Inc. News
BIAF Breaking Stock News: Dive into BIAF Ticker-Specific Updates for Smart Investing
Business Wire
8 days ago
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
Business Wire
18 days ago
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
MT Newswires
23 days ago
bioAffinity Technologies Secures Japanese Patent for Lung Cancer Diagnostic Method
Business Wire
23 days ago
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
PR Newswire
a month ago
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
Business Wire
a month ago
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
PR Newswire
a month ago
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
Business Wire
a month ago
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
Compare BIAF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIAF bioAffinity Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.